Global Information
회사소개 | 문의 | 비교리스트

망막색소변성증(망막염) : 파이프라인 리뷰

Retinitis Pigmentosa (Retinitis) (Ophthalmology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 200486
페이지 정보 영문 318 Pages 배송안내
가격
US $ 2,500 ₩ 3,185,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,371,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 9,556,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


망막색소변성증(망막염) : 파이프라인 리뷰 Retinitis Pigmentosa (Retinitis) (Ophthalmology) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 318 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

망막색소변성증(RP)은 망막에 작용하는 일련의 유전성 안과질환에 붙여진 명칭입니다. RP에 걸리면 광수용체 세포(망막 내부의 빛을 감지하는 세포)가 파괴되는데, 광수용체 세포는 빛을 포착, 처리해서 눈이 보이게 하는 효과가 있기 때문에 광수용체 세포 파괴와 괴사는 진행성 시력 소실을 초래합니다. 각종 RP의 공통된 특징은 간체세포(희미한 빛을 탐지하는 망막세포)와 추체세포(빛과 색체를 탐지하는 망막세포)의 단계적 손실인데, 처음 단계에서는 대부분 간체세포가 손실됩니다. 이러한 형태의 RP는 처음에 야맹증에서부터 시작됩니다. 야맹증이란 우리들이 밝은 야외에서 어두운 영화관에 들어갔을 때 느끼는 감각과 비슷한 증상입니다.

세계 각국에서의 망막색소변성증증(망막염)(Retinitis Pigmentosa(Retinitis)) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 각 임상시험 단계 제품 목록, 주요 기업 개요, 주요 약제 개요(제품 개요, 작용기서, 연구개발(R&D) 진전 상황), 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 분석 범위

망막색소변성증(망막염) 개요

치료제 개발

  • 망막색소변성증(망막염)용 파이프라인 제품 : 개요
  • 망막색소변성증(망막염)용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 망막색소변성증(망막염) 치료제

대학/연구기관에서 연구중인 망막색소변성증(망막염) 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

망막색소변성증(망막염) 치료제 : 개발중인 제품 목록(기업별)

망막색소변성증(망막염) 치료제 : 연구중인 제품 목록(대학/연구기관별)

망막색소변성증(망막염) 치료제 개발에 참여하고 있는 기업

  • Acucela Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Amgen Inc.
  • Applied Genetic Technologies Corporation
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Caladrius Biosciences, Inc.
  • Dompe Farmaceutici S.p.A.
  • Genable Technologies Limited
  • Genethon
  • GenSight Biologics S.A.
  • Grupo Ferrer Internacional, S.A.
  • ID Pharma Co., Ltd.
  • InFlectis BioScience
  • International Stem Cell Corporation
  • Ionis Pharmaceuticals, Inc.
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Nanovector s.r.l.
  • Orphagen Pharmaceuticals, Inc.
  • QLT Inc.
  • RegenxBio Inc.
  • ReNeuron Group Plc
  • SanBio, Inc.
  • Sanofi
  • Shire Plc
  • Spark Therapeutics, Inc.
  • Staidson(Beijing) Biopharmaceuticals Co.,td.
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd

망막색소변성증(망막염) : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

약제 개요

망막색소변성증(망막염) 치료제 : 최신 파이프라인 동향

망막색소변성증(망막염) 치료제 : 개발이 휴지 상태인 제품

망막색소변성증(망막염) 치료제 : 개발이 중지된 제품

망막색소변성증(망막염) 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

KSM 16.07.11

List of Tables

List of Tables

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, 2021
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, 2021 (Contd..1)
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, 2021 (Contd..2)
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2021, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 15, 3, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 10 and 2 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Retinitis Pigmentosa (Retinitis) - Overview
  • Retinitis Pigmentosa (Retinitis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
  • Retinitis Pigmentosa (Retinitis) - Drug Profiles
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products
  • Retinitis Pigmentosa (Retinitis) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q